中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

10 records (took 0.021 seconds)

    SYSTEM AND METHOD FOR ASSESSING FETAL ABNORMALITY BASED ON LANDMARKS
    1.
    发明申请
    SYSTEM AND METHOD FOR ASSESSING FETAL ABNORMALITY BASED ON LANDMARKS 审中-公开
    用于评估基于LANDMARK的异常异常的系统和方法

    公开(公告)号：WO2005011470A2

    公开(公告)日：2005-02-10

    申请号：PCT/US2004/024101

    申请日：2004-07-28

    Applicant: NTD LABORATORIES, INC.

    Inventor： KRANTZ, David, A. ,  ORLANDI, Francesco ,  MACRI, Vincent, James

    IPC: A61B

    CPC classification number: G06T7/0012 ,  A61B8/13 ,  G06T7/66 ,  G06T2207/10136 ,  G06T2207/20101 ,  G06T2207/30044

    Abstract: A method and system for assessing fetal abnormality based on landmarks. According to one embodiment, at least two coordinates are received for each of a plurality of points identifying a configuration of landmarks in a fetal image, and any of the received coordinates of any of the plurality of points are utilized as markers to assess fetal abnormality. According to another embodiment, at least two coordinates are received for each of a plurality of points identifying a configuration of landmarks in a fetal image, and one or more values resulting from a linear combination of any of the received coordinates of any of the plurality of points are utilized as markers to assess fetal abnormality.

    Abstract translation: 基于地标评估胎儿异常的方法和系统。 根据一个实施例，为识别胎儿图像中的界标的配置的多个点中的每一个接收至少两个坐标，并且使用多个点中的任一个的任何接收坐标作为评估胎儿异常的标记。 根据另一实施例，对于识别胎儿图像中的界标的配置的多个点中的每一个接收至少两个坐标，以及由多个点中任何一个的接收坐标的线性组合产生的一个或多个值 点用作评估胎儿异常的标记。

    METHOD FOR DETERMINING THE RISK OF PREECLAMPSIA USING PIGF-2 AND PIGF-3 MARKERS
    2.
    发明申请
    METHOD FOR DETERMINING THE RISK OF PREECLAMPSIA USING PIGF-2 AND PIGF-3 MARKERS 审中-公开
    使用PIGF-2和PIGF-3标记物确定前列腺炎风险的方法

    公开(公告)号：WO2010059952A1

    公开(公告)日：2010-05-27

    申请号：PCT/US2009/065355

    申请日：2009-11-20

    Applicant: PERKINELMER HEALTH SCIENCES, INC. ,  NTD LABORATORIES, INC. ,  WALLAC OY ,  AHOLA, Tarja ,  FRANG, Heini ,  KORPIMÄKI, Teemu ,  HURSKAINEN, Pertti ,  BOBROW, Mark N. ,  CARMICHAEL, Jonathan B.

    Inventor： AHOLA, Tarja ,  FRANG, Heini ,  KORPIMÄKI, Teemu ,  HURSKAINEN, Pertti ,  BOBROW, Mark N. ,  CARMICHAEL, Jonathan B.

    IPC: G01N33/68

    CPC classification number: G01N33/689 ,  G01N2800/368 ,  G06F19/28

    Abstract: The present invention relates to a method for determining the risk of a pregnant woman developing pre-eclampsia. The method comprises i) determining the level of one or more biochemical markers in a sample obtained from a pregnant woman, and ii) comparing the level of the at least one biochemical marker in the sample with the level of the same biochemical marker in a control sample. A difference in the level of the biochemical marker in the sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia. The isoform biochemical markers are preferably PlGF-2 and PlGF-3. The present invention relates also to a method for determining whether a pregnant woman has pre-eclampsia and as well as a kit for assessing the risk or presence of pre-eclampsia. In addition, the invention relates also to a computer program used in these determinations.

    Abstract translation: 本发明涉及一种确定孕妇发生先兆子痫风险的方法。 该方法包括：i）确定从孕妇获得的样品中的一种或多种生物化学标志物的水平，和ii）将样品中的至少一种生化标志物的水平与对照中相同生物化学标记物的水平进行比较 样品。 相对于对照样品，样品中生化标志物水平的差异表明发生先兆子痫的风险增加。 同种型生化标志物优选为PlGF-2和PlGF-3。 本发明还涉及一种用于确定孕妇是否具有先兆子痫的方法，以及用于评估先兆子痫的风险或存在的试剂盒。 此外，本发明还涉及在这些确定中使用的计算机程序。

    MULTI-MARKER SCREENING PROTOCOL FOR FETAL ABNORMALITIES
    3.
    发明申请
    MULTI-MARKER SCREENING PROTOCOL FOR FETAL ABNORMALITIES 审中-公开
    胎儿异常的多标记筛选方案

    公开(公告)号：WO2005037059A2

    公开(公告)日：2005-04-28

    申请号：PCT/US2004/031928

    申请日：2004-09-29

    Applicant: NTD LABORATORIES, INC.

    Inventor： ORLANDI, Francesco ,  KRANTZ, David, A.

    IPC: A61B

    CPC classification number: A61B8/0866 ,  A61B5/1075 ,  A61B8/0808 ,  G01N33/689 ,  G01N2800/36 ,  G01N2800/368 ,  G01N2800/387 ,  Y10S128/916

    Abstract: A method of assessing a pregnant woman's risk of having a fetus with a fetal abnormality by determining the fetus’ BPD/OFD ratio and using the BPD/OFD ratio in conjunction with one or more other screening markers for the fetal abnormality. Also provided is a method of determining whether a pregnant woman is screen­positive or screen-negative by comparing the BPD/OFD ratio of the pregnant woman’s fetus to a risk cut-off level.

    Abstract translation: 通过确定胎儿的BPD / OFD比率并将BPD / OFD比率与一种或多种其他筛选标记结合使用来评估孕妇患胎儿异常胎儿的风险的方法 胎儿异常。 还提供了一种方法，通过比较孕妇胎儿的BPD / OFD比例与风险截断水平来确定孕妇是否屏蔽和害羞;阳性或屏幕阴性。

    METHOD AND APPARATUS FOR PROVIDING QUALITY ASSURANCE AND CALIBRATION ASSURANCE IN A SPECTROPHOTOMETER
    7.
    发明公开
    METHOD AND APPARATUS FOR PROVIDING QUALITY ASSURANCE AND CALIBRATION ASSURANCE IN A SPECTROPHOTOMETER 失效
    方法和设备质量控制和校准控制分光光度计。

    公开(公告)号：EP0399012A1

    公开(公告)日：1990-11-28

    申请号：EP89912596.0

    申请日：1989-10-12

    Applicant: NTD LABORATORIES, INC

    Inventor： SORENSEN, Keld ,  MACRI, James, N. ,  DOUROS, Timothy, J. ,  SAJDA, Paul ,  IPPOLITO, Emiddio, V.

    IPC: G01N21 ,  G12B13

    CPC classification number: G01N21/274 ,  G01N21/293 ,  G01N2201/0446 ,  G01N2201/126 ,  G12B13/00

    Abstract: Un appareil destiné à assurer l'étalonnage et la qualité d'un spectrophotomètre multicanaux, notamment un spectrophotomètre ELISA, comprend une série de filtres ayant une première couleur connue et densité optique augmentant linéairement. On mesure la réaction dudit spectrophotomètre par confrontation avec la couleur connue et la densité optique augmentant linéairement. Des filtres supplémentaires d'au moins une couleur additionnelle permettent la vérification de la réaction colorée du spectrophotomètre. Un algorithme détermine si la réaction est conforme à des conditions prédéterminées. Une sortie est produite pour fournir un enregistrement de l'assurance de l'étalonnage et de la qualité du spectrophotomètre. L'invention présente une utilité particulière pour procéder à l'étalonnage et s'assurer de la qualité de spectrophotomètres ELISA utilisés dans le dépistage en laboratoire clinique de maladies infectieuses telles que l'hépatite B et les virus du SIDA.

    SYSTEM AND METHOD FOR ASSESSING FETAL ABNORMALITY BASED ON LANDMARKS
    8.
    发明公开
    SYSTEM AND METHOD FOR ASSESSING FETAL ABNORMALITY BASED ON LANDMARKS 审中-公开
    基于某些特征的系统和方法进行评估胎儿畸形

    公开(公告)号：EP1663007A2

    公开(公告)日：2006-06-07

    申请号：EP04779238.7

    申请日：2004-07-28

    Applicant: NTD Laboratories, Inc.

    Inventor： KRANTZ, David A. ,  ORLANDI, Francesco ,  MACRI, Vincent, James

    IPC: A61B8/00 ,  A61B8/12

    CPC classification number: G06T7/0012 ,  A61B8/13 ,  G06T7/66 ,  G06T2207/10136 ,  G06T2207/20101 ,  G06T2207/30044

    Abstract: A method and system for assessing fetal abnormality based on landmarks. According to one embodiment, at least two coordinates are received for each of a plurality of points identifying a configuration of landmarks in a fetal image (100), and any of the received coordinates of any of the plurality of points are utilized as markers to assess fetal abnormality (110). According to another embodiment, at least two coordinates are received for each of a plurality of points identifying a configuration of landmarks in a fetal image (200), and one or more values resulting from a linear combination of any of the received coordinates of any of the plurality of points are utilized as markers to assess fetal abnormality (210).

    METHOD FOR DETERMINING THE RISK OF PREECLAMPSIA USING PIGF-2 AND PIGF-3 MARKERS
    9.
    发明公开
    METHOD FOR DETERMINING THE RISK OF PREECLAMPSIA USING PIGF-2 AND PIGF-3 MARKERS 有权
    使用PIGF-2和PIGF-3标记物确定PREECLAMPSIA风险的方法

    公开(公告)号：EP2368119A1

    公开(公告)日：2011-09-28

    申请号：EP09760061.3

    申请日：2009-11-20

    Applicant: PerkinElmer Health Sciences, Inc. ,  NTD Laboratories, Inc. ,  WALLAC OY

    Inventor： AHOLA, Tarja ,  FRANG, Heini ,  KORPIMÄKI, Teemu ,  HURSKAINEN, Pertti ,  BOBROW, Mark N. ,  CARMICHAEL, Jonathan B.

    IPC: G01N33/68

    CPC classification number: G01N33/689 ,  G01N2800/368 ,  G06F19/28

    Abstract: The present invention relates to a method for determining the risk of a pregnant woman developing pre-eclampsia. The method comprises i) determining the level of one or more biochemical markers in a sample obtained from a pregnant woman, and ii) comparing the level of the at least one biochemical marker in the sample with the level of the same biochemical marker in a control sample. A difference in the level of the biochemical marker in the sample relative to the control sample is indicative of an increased risk of developing pre-eclampsia. The isoform biochemical markers are preferably PlGF-2 and PlGF-3. The present invention relates also to a method for determining whether a pregnant woman has pre-eclampsia and as well as a kit for assessing the risk or presence of pre-eclampsia. In addition, the invention relates also to a computer program used in these determinations.

    Abstract translation: 本发明涉及用于确定孕妇发展先兆子痫的风险的方法。 该方法包括：i）确定从孕妇获得的样品中的一种或多种生化标志物的水平，以及ii）将样品中的至少一种生化标志物的水平与对照中的相同生化标志物的水平进行比较 样品。 样品中生物化学标志物水平相对于对照样品的差异表明发生先兆子痫的风险增加。 同种型生化标志物优选为PlGF-2和PlGF-3。 本发明还涉及用于确定孕妇是否患有先兆子痫的方法以及用于评估先兆子痫的风险或存在的试剂盒。 另外，本发明还涉及用于这些确定的计算机程序。

Patent Agency Ranking